BNET Industries
Lexicon Pharmaceuticals Inc. (LXRX) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $50.1M
- Profit
- Dec 31 2007
- ($58.7M)
- Market Cap
- Sep 04 2008
- $246.2M
Latest News and Analysis
Lexicon Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript
Lexicon Pharmaceuticals Inc. LXRX Q2 2008 Earnings Call
Lexicon Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Lexicon Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Additional Resources
Zacks Analyst Blog Highlights: LoopNet Inc., Coca-Cola FEMSA S.A. de C.V., Fomento Economico Mexicano SAB de C.V., Corrections Corporation of America and Lexicon Pharmaceuticals Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: LoopNet Inc. (Nasdaq: LOOP), Coca-Cola FEMSA S.A. de C.V. (NYSE: KOF),...
Zacks Analyst Blog Highlights: Corel Corporation, Alexion Pharmaceuticals, Proctor & Gamble, Lexicon Pharmaceuticals Inc. and American Public Education, Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Corel Corporation (Nasdaq: CREL), Alexion Pharmaceuticals (Nasdaq: ALXN),...
Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
Collaboration to Apply ChemeticsR Technology to Lexicon Targets COPENHAGEN, June 10 /PRNewswire/ -- Nuevolution A/S today announced a strategic alliance with Lexicon Pharmaceuticals, Inc. aimed at the discovery of novel small molecule lead compounds for highly validated drug targets. Under the...
BioSeek Initiates Research Collaboration With Lexicon Pharmaceuticals
BURLINGAME, Calif. -- BioSeek, Inc., a pioneer in applying predictive human biology systems to drug discovery and development, announced today the initiation of a research collaboration with Lexicon Pharmaceuticals, Inc. Under the agreement, BioSeek's BioMAP[R] Systems will be used to help further evaluate selected compounds associated with several of Lexicon's...
Hot Stock Alert for Tuesday March 18, 2008.
M2 PRESSWIRE-18 March 2008-AnalystStockReport.com: Hot Stock Alert for Tuesday March 18, 2008C1994-2008 M2 COMMUNICATIONS LTD RDATE:18032008 Stocks to Watch: VIASPACE Inc. (OTCBB: VSPC), KENDLE INTL INC (Nasdaq: KNDL), INCA DESIGNS, INC. (PinkSheets: IDGI), BodyTel Scientific Inc. (OTC BB:BDYT) ,...
Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Conference Call and Webcast to Follow THE WOODLANDS, Texas, Feb. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. will release its fourth quarter and year end 2007 financial results on Thursday, March 6, 2008 after the financial markets close. Lexicon management will hold a conference call to...
Zacks Analyst Interview Highlights: Amgen, GlaxoSmithKline and Lexicon Pharmaceuticals
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Amgen (Nasdaq: AMGN), GlaxoSmithKline (NYSE: GSK) and Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX). A synopsis of today's Analyst Interview is presented below. The full article can be read at www.zacks.com. ...
Sequenom Reports Third Quarter 2007 Financial Results
Completes $30 Million Private Placement Conference Call Begins Today at 4:30 p.m. Eastern Time SAN DIEGO -- Sequenom, Inc. (NASDAQ:SQNM) today reported financial results for the three and nine months ended September 30, 2007. The Company also announced completion of the previously announced...
BIO Investor Forum 2007 Conference Provides Insights Into Investment Pipeline
WASHINGTON -- The Biotechnology Industry Organization BIO today announced the moderators and panelists delivering the opening plenary session, Check Your Options: Raising Public and Private Financing in Today's Marketplace, at the BIO Investor Forum 2007. The conference will take place October 9-11, at the Palace Hotel in...
Zacks Analyst Interview Highlights: Lexicon Pharmaceuticals, Critical Therapeutics and Sangamo Biosciences
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Lexicon Pharmaceuticals (Nasdaq: LEXG), Critical Therapeutics (Nasdaq: CRTX) and Sangamo Biosciences (Nasdaq: SGMO). A synopsis of today's Analyst Interview is presented below. The full article can be...
BioLineRx Adds Three Industry Experts to Its Board of Directors
JERUSALEM -- BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, announced today that Tamar Howson, Gil Bianco and Ilan Leviteh have been appointed to the Company's board of directors. Ms. Howson brings to BioLineRx more than 20 years of pharmaceutical and biotech industry experience. Ms....
Lexicon Pharmaceuticals, Inc Announces Potential New Therapy.
M2 PRESSWIRE-4 July 2007-FINANCIALS: Lexicon Pharmaceuticals, Inc Announces Potential New TherapyC1994-2007 M2 COMMUNICATIONS LTD RDATE:05072007 InvestorIM has been created as a tool for the average investor. The idea is simple, a website where the world can communicate. Do you have a ...
Friday's Featured Stock: nCoat, Inc. (OTCBB: NCOA).
M2 PRESSWIRE-4 July 2007-SmallCapStockAnalyst.com: Friday's Featured Stock: nCoat, Inc. (OTCBB: NCOA)C1994-2007 M2 COMMUNICATIONS LTD RDATE:06072007 Stocks to Watch: nCoat, Inc. (OTCBB: NCOA), Sharper Image Corporation (Nasdaq:SHRP) , Who's Your Daddy, Inc. (OTC BB:WYDY), Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) , Diomed Holdings,...
Market Commentary on Lexicon Pharmaceuticals, Inc.
M2 PRESSWIRE-3 July 2007-Biotech News: Market Commentary on Lexicon Pharmaceuticals, IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:03072007 Market Commentary on Lexicon Pharmaceuticals, Inc (NASDAQ:LXRX) Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of pharmaceutical products for the...
Zacks Analyst Interview Highlights: Sangamo Bioscience, Lexicon Pharmaceuticals and Critical Therapeutics
CHICAGO -- Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Sangamo Bioscience (Nasdaq: SGMO), Lexicon Pharmaceuticals (Nasdaq: LXRX) and Critical Therapeutics (Nasdaq: CRTX). A synopsis of today's Analyst Interview is presented below. The full article can be read at http://at.zacks.com/?id=2678....
Kathleen M. Wiltsey Named to Sequenom Board of Directors
SAN DIEGO -- Sequenom, Inc. (NASDAQ:SQNM) today announced that Kathleen M. Wiltsey has been elected to the Company's board of directors. "Kathleen brings significant biotechnology commercialization experience to Sequenom and we plan to call upon her experience in launching and marketing two leading biotechnology products...
nCoat Signs Definitive Agreement to Acquire Metallic Ceramic Coatings, Inc.
M2 PRESSWIRE-20 June 2007-SmallCapStockAnalyst.com: nCoat Signs Definitive Agreement to Acquire Metallic Ceramic Coatings, Inc.C1994-2007 M2 COMMUNICATIONS LTD RDATE:20062007 Stocks to Watch: nCoat, Inc. (OTCBB: NCOA), Far East Energy Corp. (OTCBB: FEEC), LMI Aerospace Inc. (Nasdaq:LMIA) , Patriot Scientific Corporation (OTCBB:...
Open Energy (OTCBB: OEGY) Receives Price Target of $1.25.
M2 PRESSWIRE-20 June 2007-LiquidStockReport.com: Open Energy (OTCBB: OEGY) Receives Price Target of $1.25C1994-2007 M2 COMMUNICATIONS LTD RDATE:20062007 Stocks to Watch: Open Energy Corporation (OTCBB: OEGY) , Far East Energy Corp. (OTCBB: FEEC), LMI Aerospace Inc. (Nasdaq:LMIA) , Patriot Scientific Corporation...
- Next »
- page 1 of 1
- « Previous
Sort byClose
- Incorporated: 1995
- CEO: Dr. Arthur T. Sands Ph.D.
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of treatments for human disease. Co. utilizes its proprietary gene knockout technology to discover the physiological and behavioral functions and utility of the proteins encoded by the corresponding human genes as potential drug targets. As of Dec 31 2007, Co.'s product candidates include LX6171, for the potential treatment for cognitive impairment, LX1031, for the potential treatment for gastrointestinal disorders, LX1032, for the potential treatment for carcinoid syndrome, and LX2931, for the potential treatment for autoimmune diseases such as rheumatoid arthritis.
Key Competitors
Lexicon Pharmaceuticals Inc. Company Info
Board of Directors
Dr. Samuel L. Barker Ph.D.
Chairman
Mr. Frank P. Palantoni
Dr. Arthur T. Sands Ph.D.
Mr. Christopher J. Sobecki
Dr. Judith L. Swain
Ms. Kathleen M. Wiltsey
Mr. Philippe J. Amouyal
Mr. Raymond Debbane
Dr. Robert J. Lefkowitz M.D.
Dr. Alan S. Nies M.D.
Contact Information
8800 Technology Forest Place
The Woodlands, TX
http://www.lexicon-genetics.com
281 863-3000